Agios Pharmaceuticals, Inc.

AGIO Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
AGIO Income Statement
AGIO Balance Sheet
AGIO Cash Flow
Congress Trading

Recent trades of AGIO by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jan. 24, 2024
Thomas MacArthur House / R Sale $1,001 - $15,000 May. 27, 2015
Thomas MacArthur House / R Purchase $1,001 - $15,000 Mar. 18, 2015
AGIO Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
AGIO Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AGIO Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AGIO's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $40,000 Oct 16, 2023 Issue: None
  • $40,000 Jul 14, 2023 Issue: None
  • $40,000 Apr 20, 2023 Issue: None
  • $40,000 Jan 14, 2023 Issue: None
  • $40,000 Oct 16, 2022 Issue: None
  • $40,000 Jul 15, 2022 Issue: None
  • $40,000 Apr 15, 2022 Issue: None
  • $40,000 Jan 15, 2022 Issue: Health Issues
  • $40,000 Oct 15, 2021 Issue: Health Issues
  • $40,000 Jul 17, 2021 Issue: None
  • $30,000 Apr 17, 2021 Issue: None
  • $20,000 Jan 11, 2012 Issue: Budget/Appropriations Defense Health Issues
  • $20,000 Oct 14, 2011 Issue: Defense Health Issues Budget/Appropriations
  • $20,000 Oct 12, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $30,000 Jul 16, 2010 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $30,000 Apr 18, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $30,000 Jan 06, 2010 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $30,000 Oct 13, 2009 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $30,000 Jul 19, 2009 Issue: Medical/Disease Research/Clinical Labs
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Pyruvate kinase activators for use in treating blood disorders Nov. 05, 2024
  • Patent Title: Pyruvate kinase activators for use in treating blood disorders Apr. 16, 2024
  • Patent Title: Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Mar. 05, 2024
  • Patent Title: Mitapivat therapy and modulators of cytochrome p450 Jan. 23, 2024
  • Patent Title: Pyruvate kinase modulators and use thereof Jan. 16, 2024
  • Patent Title: Therapeutic compounds and compositions Jan. 09, 2024
  • Patent Title: Pyruvate kinase activators for use in therapy Oct. 24, 2023
  • Patent Title: Therapeutic compounds and compositions Jul. 18, 2023
  • Patent Title: Pyruvate kinase activators for use in treating blood disorders Feb. 28, 2023
  • Patent Title: Pyruvate kinase modulators and use thereof Oct. 11, 2022
  • Patent Title: Methods of treating brain tumors using combination therapy Oct. 04, 2022
  • Patent Title: Pyruvate kinase activators for use in treating blood disorders Jun. 21, 2022
  • Patent Title: Crystalline forms of n-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide Feb. 22, 2022
  • Patent Title: Methods of using pyruvate kinase activators Feb. 01, 2022
  • Patent Title: Pyruvate kinase activators for use in treating blood disorders Jun. 22, 2021
  • Patent Title: Therapeutically active compounds and their methods of use Jun. 01, 2021
  • Patent Title: Therapeutic compounds and compositions Apr. 27, 2021
  • Patent Title: Therapy for treating malignancies Apr. 20, 2021
  • Patent Title: Therapeutically active compounds and their methods of use Mar. 16, 2021
  • Patent Title: Combination therapy for treating malignancies Feb. 02, 2021
  • Patent Title: Inhibitors of cellular metabolic processes Oct. 13, 2020
  • Patent Title: Pharmaceutical compositions of therapeutically active compounds Oct. 13, 2020
  • Patent Title: Methods of treating brain tumors using combination therapy Sep. 22, 2020
  • Patent Title: Therapeutically active compounds and their methods of use Aug. 04, 2020
  • Patent Title: Therapeutically active compounds and their methods of use Jul. 21, 2020
  • Patent Title: Methods for diagnosing idh-mutant cell proliferation disorders Jul. 14, 2020
  • Patent Title: Therapeutically active compounds and their methods of use Jun. 23, 2020
  • Patent Title: Compounds and their methods of use Jun. 23, 2020
  • Patent Title: Combination therapy for treating malignancies May. 19, 2020
  • Patent Title: Therapeutically active compositions and their methods of use May. 05, 2020
  • Patent Title: Pharmaceutical compositions of therapeutically active compounds Oct. 22, 2019
  • Patent Title: Therapeutically active compounds and their methods of use Oct. 08, 2019
  • Patent Title: Glutaminase inhibitors and method of use Sep. 17, 2019
  • Patent Title: 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer Aug. 13, 2019
  • Patent Title: Inhibitors of cellular metabolic processes Jun. 25, 2019
  • Patent Title: Therapeutically active compounds and their methods of use May. 21, 2019
  • Patent Title: Therapeutic compounds and compositions Feb. 12, 2019
  • Patent Title: Therapeutically active compounds and their methods of use Feb. 12, 2019
  • Patent Title: Methods of treatment of malignancies Jan. 29, 2019
  • Patent Title: Therapeutically active compounds and their methods of use Jan. 08, 2019
  • Patent Title: N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer Oct. 30, 2018
  • Patent Title: Therapeutically active compounds and their methods of use Oct. 23, 2018
  • Patent Title: Methods of evaluating patients using e-cadherin or vimentin Oct. 16, 2018
  • Patent Title: Therapeutically active compounds and their methods of use Oct. 09, 2018
  • Patent Title: Compounds and their methods of use Oct. 02, 2018
  • Patent Title: Bicyclic pkm2 activators Oct. 02, 2018
  • Patent Title: Therapeutic compounds and compositions Jul. 24, 2018
  • Patent Title: Therapeutically active compounds and their methods of use Jul. 24, 2018
  • Patent Title: Therapeutically active compounds and their methods of use Jul. 10, 2018
  • Patent Title: Glutaminase inhibitors and method of use Jul. 03, 2018
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of AGIO in WallStreetBets Daily Discussion

AGIO News

Recent insights relating to AGIO

CNBC Recommendations

Recent picks made for AGIO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AGIO

AGIO Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AGIO Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top